ALHAMMADI
Al Hammadi Holding
As of: May 28, 2026
Company Profile
Al Hammadi Holding Company is a Saudi joint stock company that manages subsidiaries, invests in securities, and owns/operates real estate and healthcare facilities. Its core operations include medical services through Al Hammadi Hospital branches and pharmaceutical product sales. The company provides support, loans, and guarantees to its subsidiaries and holds various intangible rights like patents and trademarks.
The Story
A diversified healthcare leader balancing stable hospital operations with high-growth specialized medical ventures and pharmaceutical investments.
Source: Annual 2025 (2026-03-31)
Performance & Distributions
Market Pricing Multiples
Growth Story
Revenue reached 1.23 billion SAR in fiscal 2025, representing a steady climb from 1.15 billion SAR in 2024, primarily fueled by a 31% surge in pharmaceutical sales. While the company's 5-year average reinvestment rate of 17.3% yields a sustainable growth rate of 2.3%, the narrative is shifting toward aggressive inorganic expansion. This is highlighted by the 113 million SAR acquisition of a 40% stake in Wareed Health Company to capture the home healthcare market and a 54.5 million SAR partnership with AC Milan to launch specialized rehabilitation centers. Furthermore, the planned IPO of its 35%-owned associate, Sudair Pharmaceutical, underscores a strategy to crystallize value from its long-term investments in drug manufacturing.
Profitability Dynamics
Al Hammadi continues to be a consistent value creator, maintaining a 5-year average ROIC of 13.3% against a WACC of 8.2%, resulting in a positive value gap of 5.1%. Profitability remains robust with TTM operating margins of 20.9%, even as net income moderated to 241.9 million SAR in 2025 from 338.8 million SAR the previous year, partly due to a 4.3 million SAR goodwill impairment. The medical services segment remains the core profit driver, generating over 301 million SAR in gross profit. This strong cash generation capability allowed the company to distribute 200 million SAR in interim dividends throughout 2025 while simultaneously funding its capital-intensive expansion projects.
Risk & Capital Structure
Risk Factors
The company's risk profile is characterized by a low beta of 0.89 and a unique debt structure that utilizes interest-free loans from the Ministry of Finance to fund hospital infrastructure. However, liquidity is closely tied to the public sector, with 99% of the 539.5 million SAR in net trade receivables due from government and insurance entities, which are subject to extended payment cycles. Business-specific risks include the integration of the newly acquired Wareed Health network and the long-term financial commitments of the AC Milan agreement. Additionally, the company maintains a provision for expected credit losses of 102.4 million SAR, reflecting the inherent risks in its large-scale receivables portfolio.
Governance Disclosures
We track 6 key governance and oversight matters for this company in our database.
Related Party Rental and Purchase Transactions
The Group paid SAR 12,900,000 in rental expenses to major shareholders and SAR 700,000 to their relatives during 2025. Additionally, the Group made purchases totaling SAR 4,254,475 from companies owned by major shareholders and their relatives.
Related Party Balances and Clinical Services
The company maintains outstanding balances with related parties, including SAR 424,932 due from main shareholders and SAR 581,427 due to related parties. It also provided clinical services to shareholders valued at SAR 419,889.
Research Report
Read our independent analysis →Explore ALHAMMADI's Full Profile
Usool Research tracks ALHAMMADI's financials, governance disclosures, valuation metrics, and more. Structured and updated from every filing.
Start Exploring → Sign up free and explore the data.